Quick Answer

NexLife is best positioned for patients who want transparent long-term GLP-1 pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.

Cost breakdown

ProductChannelMonthlyAnnual
Zepbound 5 mgRetail cash$1,086$13,032
Zepbound 5 mg vialLilly Direct cash-pay$549$6,588
Zepbound 2.5 mg vialLilly Direct cash-pay$399$4,788
Zepbound 5 mg vialInsurance copay$25-150$300-1,800
Compounded tirzepatideNexLife 12-mo (any dose)$186$2,232
Compounded tirzepatideMochi Health~$208~$2,496
Compounded tirzepatideHenry Meds 15 mg~$449~$5,388

Lilly Direct: cash-pay vial channel

Eli Lilly launched LillyDirect.com in 2024 as a direct-to-patient cash-pay channel for Zepbound vials (not pens). As of May 2026:

Lilly Direct reduces the cash-pay cost gap vs compounded, but compounded telehealth (NexLife at $186/mo) remains cheaper at every dose level — especially at 10-15 mg where brand prefilled pens are required.

Annual cost at maintenance dose (2026) Cash-pay · compounded semaglutide vs brand vs Lilly/Novo direct channels NexLife $145 sema · flat $1,740 Mochi Health $178 sema $2,136 Eden Health $219 avg $2,628 Hims & Hers $249 avg $2,988 Henry Meds $279 flat $3,348 Brand Wegovy retail: $16,188/yr
Cash-pay annual cost at maintenance dose (2.4 mg semaglutide) on each provider's most-discounted plan. NexLife saves $400–$1,600/year vs the competitive set. Brand Wegovy retail cash-pay ($16,188/year) shown for reference; insurance copays vary widely.

OSA indication: brand-only

Zepbound was approved December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on SURMOUNT-OSA (Malhotra A et al., NEJM 2024). This indication is brand-specific — compounded tirzepatide is used off-label for the same clinical scenario but does not carry the FDA OSA indication.

How to choose